Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Myc influences metastatic heterogeneity in pancreatic cancer.

PROVIDER: PRJNA646156 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12215500.fastq.gz	Fastqsanger.gz
	SRR12215501.fastq.gz	Fastqsanger.gz
	SRR12215502.fastq.gz	Fastqsanger.gz
	SRR12215503.fastq.gz	Fastqsanger.gz
	SRR12215504.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 130

Similar Datasets

Project description:Myc influences metastatic heterogeneity in pancreatic cancer.

| PRJNA646123 | ENA

Metastatic site influences driver gene function in pancreatic cancer

Project description:Metastatic site influences driver gene function in pancreatic cancer

| PRJNA1030027 | ENA

Blimp1 induces transient metastatic heterogeneity in pancreatic cancer

Project description:Blimp1 induces transient metastatic heterogeneity in pancreatic cancer

| PRJNA356058 | ENA

Large-scale epigenetic reprogramming is punctuated late during the evolution of pancreatic cancer progression [BS-Seq]

Project description:During pancreatic cancer progression, heterogeneous subclonal populations evolve in the primary tumor that possess differing capacities to metastasize and cause patient death. However, the genetics of metastasis reflects that of the primary tumor, and PDAC driver mutations arise early. This raises the possibility than an epigenetic process could be operative late. Using an exceptional resource of paired patient samples, we found that different metastatic subclones from the same patient possessed remarkably divergent malignant properties and global epigenetic programs. Global reprogramming was targeted to thousands of large chromatin domains across the genome that collectively specified malignant divergence. This was maintained by a metabolic shift within the pentose phosphate pathway, independent of KRAS driver mutations. Analysis of paired primary and metastatic tumors from multiple patients uncovered substantial epigenetic heterogeneity in primary tumors, which resolved into a terminally reprogrammed state in metastatic lesions. This supports a model whereby driver mutations accumulate early to initiate pancreatic tumorigenesis, followed by a period of subclonal evolution that generates sufficient intra-tumor heterogeneity for selection of epigenetic programs that may increase fitness during malignant progression and metastatic spread. To map the epigenomic landscape of pancreatic cancer progression as it evolves within patients. BS-Seq of 4 patients (A13, A38, A124 and A125). Patient A38 included local peritoneal metastasis and 2 distant metastsis (liver and lung mets). Patient A13 included 2 primary tumors and 1 distant lung metastasis. Each sample has been done with replicates. Patient A124 included 2 primary tumors and 1 normal pancreas.

2016-10-24 | E-GEOD-63123 | biostudies-arrayexpress

Large-scale epigenetic reprogramming is punctuated late during the evolution of pancreatic cancer progression [ChIP-Seq]

Project description:During pancreatic cancer progression, heterogeneous subclonal populations evolve in the primary tumor that possess differing capacities to metastasize and cause patient death. However, the genetics of metastasis reflects that of the primary tumor, and PDAC driver mutations arise early. This raises the possibility than an epigenetic process could be operative late. Using an exceptional resource of paired patient samples, we found that different metastatic subclones from the same patient possessed remarkably divergent malignant properties and global epigenetic programs. Global reprogramming was targeted to thousands of large chromatin domains across the genome that collectively specified malignant divergence. This was maintained by a metabolic shift within the pentose phosphate pathway, independent of KRAS driver mutations. Analysis of paired primary and metastatic tumors from multiple patients uncovered substantial epigenetic heterogeneity in primary tumors, which resolved into a terminally reprogrammed state in metastatic lesions. This supports a model whereby driver mutations accumulate early to initiate pancreatic tumorigenesis, followed by a period of subclonal evolution that generates sufficient intra-tumor heterogeneity for selection of epigenetic programs that may increase fitness during malignant progression and metastatic spread. To map the epigenomic landscape of pancreatic cancer progression as it evolves within patients. Chip-Seq (K27Me3, K36Me3, K9Me2/3, K4Me3 and K27Ac) of 2 patients (A13 and A38) and HPDE cell line. Patient A38 included local peritoneal metastasis and 2 distant metastsis (liver and lung mets), and 6AN treated and DMSO samples for lung matastasis. Patient A13 included 2 primary tumors and 1 distant lung metastasis. Each sample has been done with replicates.

2016-10-24 | E-GEOD-63125 | biostudies-arrayexpress

Metastatic site influences driver gene function in pancreatic cancer [scMultiome]

Project description:Metastatic site influences driver gene function in pancreatic cancer [scMultiome]

| PRJNA1030031 | ENA

Metastatic site influences driver gene function in pancreatic cancer [RNA-seq]

Project description:Metastatic site influences driver gene function in pancreatic cancer [RNA-seq]

| PRJNA1030030 | ENA

Metastatic site influences driver gene function in pancreatic cancer [ATAC-seq]

Project description:Metastatic site influences driver gene function in pancreatic cancer [ATAC-seq]

| PRJNA1030029 | ENA

Metastatic site influences driver gene function in pancreatic cancer [scRNA-seq]

Project description:Metastatic site influences driver gene function in pancreatic cancer [scRNA-seq]